Bullets

 

February 4, 2015

Individual customers: New 2015 prior authorization requirements for high dose narcotics on the Select Drug Program formulary

Good morning.  Independence Blue Cross has provided us with the following alert about new requirements for specific high dose narcotics on the Select Drug Program Formulary.  Please review the information below.  

 

Effective January 1, 2015, certain prescription medications (high dose narcotics) from our Select Drug Program® formulary required prior authorization.* Due to the unique nature of these medications, impact to existing users has been delayed to allow patients with active prescriptions time to discuss their options with their health care provider. Therefore up until now, the only members affected by this requirement were those with prescriptions starting after January 1, 2015.

Now, we are in the process of alerting affected members and their healthcare providers of the prior authorization requirement as it takes effect.

Which medications are affected by this change?
The following brand and generic medications are affected by this change:

 

Brand Name

Generic Name

Applicable Strength

Avinza®

Morphine sulfate ER capsule 24HR

120mg

Dilaudid®

Hydromorphone immediate release

4mg, 8mg

Duragesic® Patch

Fentanyl transdermal patch 72 HR

25mcg, 50mcg, 75mcg, 100mcg

Exalgo®

Hydromorphone tablet ER 24HR Abuse deterrent

8mg, 12 mg, 16mg and 32mg

Kadian®

Morphine sulfate ER 24HR capsule

60mg, 80mg, 100mg, 200mg

Various (Methadose™)

Methadone

All strengths

Morphine Sulfate tab

 

Morphine Sulfate tablet

 

30mg

MS Contin®

Morphine sulfate extended release tab

60mg, 100mg, 200mg

Nucynta®

Tapendatol immediate release

100mg

Nucynta® ER

Tapendatol extended release

150mg, 200mg, 250mg

Opana®

Oxymorphone

10mg

Opana® ER

Oxymorphone

20mg, 30mg, 40mg

Oxy IR

Oxycodone immediate release

30mg

Oxycontin®

Oxycodone Extended-release

30mg, 40mg, 60mg, 80mg

 

Which members were affected by this change?
Approximately 60% of the members affected by this change are individual customers. Primary agents and producing agents with group customers affected by the change were previously notified by their Independence Blue Cross account executive.

How are we communicating this change to members?
We will be sending a letter to affected members to advise them of the change. The letter will list the medication(s) the member currently takes that will require prior authorization and specify the options for continuing therapy. The letter will be sent to members at least 30 days in advance of the date their prior authorization requirement takes effect.

Letters will be sent according to the following schedule:

Mailing dates for members whose authorization ends on 3/31/15:

  • January 26
  • February 2 and 16

Mailing dates for members whose authorization ends on 6/30/15:

  • March 2, 16, and 30
  • April 13 and 27
  • May 11 and 25

How are we communicating this change to healthcare providers?
We will be sending a letter to providers who have patients affected by this change. It will include a list of affected patients and the medication(s) that will require prior authorization.

The letters will be sent out on the following dates:

To providers with members whose authorization ends on 3/31/15:

  • January 26

To providers with members whose authorization ends on 6/30/15:

  • March 2
  • April 13

 

If you have any questions, please contact your dedicated Account Executive

 

David

        Jon

Shannan

Barb

Alice

Kristin

      Larry

Banet

McLaughlin

Herman

Kates

Banet

Johnson

  Turnbull

 

  

*Nothing contained in Healthy Living should be considered, or used as a substitute for, medical advice, diagnosis or treatment. Healthy Living is provided to highlight lifestyle choices that may affect persons' daily lives. Healthy Living does not constitute the practice of any medical, nursing or other professional health care advice, diagnosis or treatment. We advise you to always seek the advice of a physician or other qualified health care provider with any questions regarding personal health or medical conditions. Never disregard, avoid or delay in obtaining medical advice.